Valerian composition and related methods
A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.
1. A composition comprising a therapeutically effective pharmaceutical dosage form having:
a solid core including valerian within an acidified polymer matrix;
an expedited release portion including a first fraction of the valerian, the expedited release portion being effective to release the first fraction within about 2 hours from placement in a 0.1 N HCl solution; and
a sustained release portion including a second fraction of the valerian, the sustained release portion being effective to release the second fraction from at least 2 to within about 10 hours from placement in a phosphate buffer with a pH of 6.8;
the pharmaceutical dosage form being selected from a tablet and a capsule;
the acidified polymer matrix comprising:
at least one acidifying agent selected from the group consisting of citric acid, succinic acid, tartaric acid, phosphoric acid, and hydrochloric acid; and
at least one hydrogel-forming polymer selected from the group consisting of a carboxymethylcellulose, a methylcellulose, a hydroxypropylcellulose, a hydroxypropylmethylcellulose, a hyaluronate, an alginate, a pectin, a poloxamer, a poloxamine, an ethylene vinyl acetate, a polyethylene glycol, a dextran, a polyvinylpyrrolidone, a chitosan, a polyvinylalcohol, a propylene glycol, a polyvinylacetate, a polylactic acid, and a polyhydroxybutyric acid;
wherein the acidified polymer matrix includes a valerian stability improving amount of the acidifying agent that makes the pharmaceutical dosage form storage stable by reducing degradation of the valerian when the pharmaceutical dosage form is stored at 25 degrees C. and 60% relative humidity.
2. The composition of claim 1 , wherein the first fraction of the valerian is 5% to 50% of the valerian and the second fraction of the valerian is the remainder of valerian in the pharmaceutical dosage form.
3. The composition of claim 1 , wherein the acidified polymer matrix has a pH of 2 to 5.
4. The composition of claim 1 , wherein the acidified polymer matrix has a pH of 3 to 5.
5. The composition of claim 1 , wherein the hydrogel-forming polymer swells upon absorption of water.
6. The composition of claim 1 , wherein the pharmaceutical dosage form includes about 150 mg to about 250 mg of valerian.
7. The composition of claim 1 , wherein:
valerian is 15% w/w to 45% w/w of the pharmaceutical dosage form; an acidifying agent in the acidified polymer matrix is 1% w/w to 20% w/w of the pharmaceutical dosage form; and
a polymer of the acidified polymer matrix is 1% w/w to 15% w/w of the pharmaceutical dosage form.